BIOD-238

BIOD-238 is an **ultra-rapid-acting insulin analogue formulation** developed by combining Biodel's proprietary excipients with the marketed formulation of insulin lispro (Humalog®). The intent is to substantially accelerate its absorption compared to Humalog®, resulting in a pharmacokinetic profile with faster onset and shorter duration of peak concentration. Mechanistically, BIOD-238 functions as an agonist at the insulin receptor to mediate glucose lowering. Clinical studies report that BIOD-238 achieves double the insulin absorption over the first 30 minutes post-injection compared to Humalog®, with a significant reduction in time to half-maximal and maximal insulin concentrations. Injection site tolerability is slightly less favorable than Humalog®, but overall tolerability is considered comparable. BIOD-238 was evaluated clinically in patients with Type 1 diabetes in a Phase 1 trial. The developer is Biodel, later merged into Albireo Pharma[1][3][5].

Brand names

BIOD-238BIOD238BIOD 238

Other names

Ultra-rapid-acting insulin analogue